Condylox Research News

Combination therapy with mitoxantrone and etoposide in refractory acute myelogenous leukemia.

We have investigated the efficacy of mitoxantrone in combination with etoposide in patients with refractory acute myelogenous leukemia. The regimen consisted of 10 mg/m2/day of mitoxantrone given iv on Days 1-5; and 100 mg/m2/day of etoposide as short infusion, initially on Days 1-3 and extended to Days 4 and 5 as appropriate. Of the 26 patients treated with this combination, nine (34.6%) have achieved complete remission and two have achieved partial remission. The median duration of continuous complete remission was 85 days (range, 21-183+). Toxicity was mild and only one case of early death was observed. This combination seems to be an active regimen in refractory acute myelogenous leukemia, and its incorporation in front-line therapy seems warranted.

Journal ISSN: 0361-5960 Issue: 70-8 (1986) Pages: 1025-7

Monocytic skin infiltration in chronic myelomonocytic leukaemia.

Although leukaemic infiltration of the skin commonly occurs in acute monoblastic leukaemia, the association with chronic myelomonocytic leukaemia (CMML) has only been described recently. We confirm the association and report histologically proven monocytic infiltration of the skin in four patients with CMML. This did not herald a more aggressive phase of the disease as previously suggested. Treatment of the rash with low dose cytarabine or etoposide was effective but razoxane produced no benefit. Superficial radiotherapy was useful to control pruritus in one patient.

Journal ISSN: 0141-9854 Issue: 8-2 (1986) Pages: 115-9

[Full remission of acute non-lymphatic leukemia lasting for 16 months following combination therapy with aclacinomycin A]

After pretreatment with anthracyclines, a boy entered a second complete remission of an acute myeloid leukemia lasting already for 16 months following chemotherapy with Aclacinomycin A combined with Etoposide, Cytosine Arabinoside and Thioguanine. The newly developed Aclacinomycin A was well tolerated. Presumably there is no cross resistance between Aclacinomycin A and the anthracyclines, the latter being in use for the therapy of leukemias since some time.

Journal ISSN: 0026-9298 Issue: 134-8 (1986) Pages: 547-9